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Introduction: Obstructive sleep apnea (OSA) and its cardiometabolic alterations are 
closely associated with visceral obesity. Patients with OSA frequently present with 
symptoms of depression and anxiety. Although these subjective symptoms of OSA are 
the result of complex biological dysregulation, it remains unclear if they have a direct effect 
on the dysfunction of adipose tissue.
Methods: In a pilot, prospective, randomized study, we evaluated 10 recently diagnosed 
male patients with severe OSA by full polysomnography (PSG) and 4 male non-apneic 
subjects matched for age and body mass index (BMI) with abdomen adipose tissue 
biopsies. Subjects with diabetes/prediabetes and cardiovascular and psychiatric diseases 
and who are current smokers were excluded. All patients underwent anthropometric 
measurements and completed the following questionnaires: Epworth Sleepiness Scale 
(ESS), Fatigue Severity Scale (FSS), and Hospital Anxiety and Depression Scale (HADS-A 
and HADS-D). Fasting venous blood samples were collected on the day after PSG, 
between 8:00 and 9:00 a.m., after an overnight fast. Fat biopsies were performed at the 
same time periods and adipose tissue samples of 300 mg were obtained from abdominal 
fat. Fat cell size, extent of fibrosis, vascularity, leukocyte common antigen inflammatory 
infiltration, and tissue macrophage accumulation were microscopically evaluated.
Results: The mean age of the group was 47.4 ± 13.8 years, with mean BMI of 35.8 ± 
4.8 kg/m2 and mean apnea-hypopnea index of 79.4 ± 46.1 events per hour of sleep 
(severe OSA). HADS-A and HADS-D scores were 5.8 ± 2.3 (3.0–8.0) and 4.7 ± 2.3 (2.0–
8.0), respectively. HADS-A score correlated positively with macrophage accumulation 
in fat biopsy (r = 0.82, p = 0.047), whereas ESS, FSS, and HADS-D did not. Severity 
of fibrosis correlated largely with waist circumference (r = -0.66, p = 0.038) and neck 
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INTRODUCTION
Obstructive sleep apnea (OSA) is a chronic condition characterized 
by repetitive collapse of the upper airway during sleep leading 
to intermittent hypoxia (IH) and recurrent arousals from sleep. 
OSA is a prevalent disorder particularly among middle-aged, 
obese men, although its existence in women as well as in lean 
individuals is increasingly recognized (1). OSA is associated with 
considerable morbidity and mortality, and numerous studies 
indicate a causal relationship between OSA and hypertension, 
cardiovascular disease, insulin resistance (IR), and diabetes 
mellitus (2).
Affective disorders such as depression and anxiety are 
commonly reported in patients with OSA. Previous studies 
hypothesized that OSA, psychological symptoms, and 
metabolic disease are the diverse consequences of underlying 
biological, metabolic, and neurologic dysregulation through 
low-grade inflammation, oxidative and nitrosative stress, and 
neurotransmitter imbalances (3–5). Each individual can express 
multiple disease states according to the underlying biological 
dysregulation (4).
For many years, adipose tissue was regarded only as an energy 
storage place. Now, visceral adipose tissue (VAT) is considered 
as a high, metabolically active tissue and a local source of pro-
inflammatory factors, closely associated with metabolic risk (6). 
Visceral obesity is associated with OSA. Apnea-hypopnea index 
(AHI) more often correlates with intra-abdominal fat than with 
subcutaneous fat in the neck region or parapharyngeal fat (7). 
Also, waist circumference is a better predictor of OSA than body 
mass index (BMI) (8). Stress-induced, glucocorticoid-mediated 
visceral obesity and metabolic syndrome manifestations are 
common in chronically stressed individuals and psychiatric 
populations due to a blunted circadian rhythm of cortisol 
secretion and mild hypercortisolism (9, 10).
The aim of our study was to evaluate the complex interactions 
among OSA, psychological symptoms, and abdominal adipose 
tissue dysfunction.
PATIENTS AND METHODS
Study Population
Ten male patients with newly diagnosed, severe OSA and four 
non-apneic male subjects, matched for age and BMI (controls), 
were selected for the present study from our outpatient clinic in the 
Department of Clinical Therapeutics, National and Kapodistrian 
University of Athens School of Medicine, Alexandra University 
Hospital of Athens. Written informed consent was obtained 
from all individual participants included in the study and the 
study protocol was approved by the Ethical Committee of the 
Alexandra University Hospital before the initiation of the study 
(approval no. 301/30.07.2013). The recruitment and assessment 
of the patients were performed by one pulmonologist (GT).
OSA was diagnosed as an AHI of ≥5 events per hour of sleep 
with associated symptoms or comorbidities or an AHI of ≥15, 
regardless of associated symptoms or comorbidities, according 
to the American Academy of Sleep Medicine  diagnostic 
criteria (11).
Exclusion criteria were known diabetes mellitus or 
fasting glycemia [fasting glucose ≥126 mg/dl or glycosylated 
hemoglobin (HbA1c) > 6.5%], current smoking, cardiovascular 
or cerebrovascular disease, uncontrolled hypertension or other 
chronic disease, known psychiatric disease, systemic medication 
use, and previous diagnosis and/or treatment for OSA and/or 
other sleep disorders.
At baseline, each patient was evaluated by medical history 
and clinical examination, underwent spirometry, and completed 
a detailed questionnaire about sleep habits.
Sleep Questionnaires
All patients answered the Epworth Sleepiness Scale (ESS), the 
Fatigue Severity Scale (FSS), and the Hospital Anxiety and 
Depression Scale (HADS). ESS is a self-report questionnaire 
that evaluates subjective sleep propensity, and a score of ≥10 
indicates excessive sleepiness (12). FSS is a method of evaluating 
the impact of fatigue in daytime functioning, and a score of ≥4 
is interpreted as abnormal, especially in subjects who suffer from 
sleep disorders (13). Finally, HADS is a reliable instrument for 
detecting and separating the states of depression and anxiety, 
by excluding somatic symptoms, in patients attending a general 
medical clinic (14). Scores of >10 are indicative of psychological 
morbidity, whereas scores between 8 and 10 are considered 
borderline.
Sleep Study
A standard full-night polysomnography (PSG) was performed 
on each patient on the same night of the initial evaluation 
circumference (r = -0.790, p = 0.006). Respiratory events correlated negatively with the 
extent of vascularization of adipose tissue (r = -0.614, p = 0.05).
Conclusions: In the preliminary results of our pilot study, we assessed that the symptoms 
of anxiety mainly contribute to macrophage accumulation, whereas the increased number 
of respiratory events reduces the extent of vascularization in visceral fat in OSA. Based 
on this observation, further larger studies are required to verify if anxious OSA patients are 
more vulnerable to the metabolic manifestations of the syndrome.
Keywords: obstructive sleep apnea, Hospital Anxiety and Depression Scale, adipose tissue, abdominal fat, biopsy
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(Alice, Respironics, Murrysville, PA). Sleep records were scored 
according to standard criteria and manually revised by an expert 
(15). Apnea was defined as a drop in the peak signal excursion 
by ≥90% of the pre-event baseline using an oronasal thermal 
sensor (diagnostic study), a positive airway pressure device 
flow (titration study), or an alternative apnea sensor when the 
duration of ≥90% drop in the sensor signal was ≥10 s. Hypopnea 
was defined as the breathing reduction of ≥30% of the pre-event 
baseline that exceeded 10 s and was associated with ≥3% oxygen 
desaturation from the pre-event baseline or with an arousal. 
Arousal was defined as an abrupt shift in electroencephalograph 
frequency, including alpha, theta, and/or frequencies greater 
than 16 Hz (but not spindles) that last at least 3 s, with at least 10 
s of stable sleep preceding the change and increased mylohyoid 
electromyographic signal of >1 s during rapid eye movement 
(REM) sleep. AHI was defined as the total number of apneas and 
hypopneas per hour of electroencephalographic sleep.
Fat Biopsy
Fasting venous blood samples were collected on the day after 
PSG, between 8:00 and 9:00 a.m., after an overnight fast, for the 
measurement of glucose, HbA1c, lipid, and liver profile. Body 
composition was analyzed with a bioelectrical impedance system 
(Siemens Acuson S 2000, Germany). Fatty liver was assessed 
by ultrasonography (Tanita bioimpedence TBF-300 body 
composition analyzer).
Fat biopsies were also performed to obtain adipose tissue 
samples (300 mg) by needle biopsy from the abdomen without 
anesthesia, as described previously (16). One block of formalin-
fixed paraffin-embedded tissue was prepared in each case 
and 4-μm-thick sections were processed. Adipose tissue was 
microscopically examined by an experienced pathologist (SS), 
unaware of the clinical information, to evaluate the fat cell size, 
extent of fibrosis, vascularity, leukocyte common antigen (LCA) 
inflammatory infiltration, and tissue macrophage accumulation. 
The size of fat cells was estimated on eosin-hematoxylin standard 
stained sections. Masson trichrome histochemical staining was 
performed for the assessment of fibrosis. Immunohistochemistry 
against CD34, LCA, and CD68 antibodies was conducted to 
depict vascular structures, B and T lymphocytes, and tissue 
macrophages, respectively. Severity of fibrosis and density of 
vascular structures, inflammatory cells, and tissue macrophages 
were semi-quantitatively assessed on a scale from 0 to 6, where 
0 corresponded to absence and 6 to the highest degree of the 
examined feature. Immunohistochemical analysis was performed 
using the EnVision Staining System (Dako, Glostrup, Denmark) 
with 3,3′-diaminobenzidine as a chromogen and a PT Link, Pre-
Treatment Module according to standard protocols. Primary 
antibody incubation was omitted as negative control. Samples 
known to strongly immunoreact to the specific antibodies were 
used as positive control.
Analysis was performed by SPSS for Windows. Normality 
was examined with the Kolmogorov-Smirnoff test. Descriptive 
results for continuous variables were expressed as mean ± SD. 
Univariate and multivariate analyses were used to determine 
possible correlations between anthropometric data, laboratory 
findings, and questionnaires’ scores and indices of apnea (AHI 
and SaO2). The OSA and the control groups were compared for 
severity of fibrosis, density of vascular structures, inflammatory 
cells, and tissue macrophages using an independent t test, and 
Cohen’s d was used to evaluate the magnitude of any difference. 
Statistical significance was defined at a level of 5% (P ≤ 0.05).
RESULTS
Baseline Characteristics of the Study 
Population
A total of 27 patients were recruited during our study period. 
Three patients refused to perform the diagnostic sleep study, 
four patients had an AHI of <5, and nine patients who refused 
fat biopsy were excluded from the study. Furthermore, women 
were excluded (n = 1) resulting in a final sample of 10 newly 
diagnosed OSA patients. A total of 4 non-apneic male subjects, 
matched for age and BMI, served as controls. The patients’ 
dispositions according to the study protocol are presented in 
Figure 1. The baseline characteristics of the study population are 
presented in Table 1. No difference was observed in any of these 
characteristics between the OSA and the control groups, except 
for forced expiratory volume in 1 s (FEV1)/forced vital capacity 
(FVC; lower score in the OSA group).
ESS score was 13.0 ± 5.3 (6.0–24.0) and 14.5 ± 4.7 (10.0–
21.0), FSS score was 3.6 ± 1.5 (1.6–5.6) and 3.4 ± 1.8 (1.5–5.6), 
HADS-A score was 5.8 ± 2.3 (3.0–8.0) and 5.5 ± 2.1 (3.0–8.0), 
and HADS-D score was 4.7 ± 2.3 (2.0–8.0) and 5.3 ± 2.8 (2.0–
8.0) in the OSA and the control groups, respectively. All patients 
suffered from severe OSA (AHI 33.7–189.4 events per hour of 
sleep). The sleep data of OSA patients are presented in Table 2. 
As expected, the AHI of the OSA group was higher (79.4 ± 46.2 
versus 2.4 ± 1.0 events per hour of sleep, respectively, p = 0.007) 
and the minSaO2 was lower than in the control group (78.7 ± 
8.4% versus 88.3 ± 1.7%, respectively, p = 0.047), whereas no 
difference was observed in the mean SaO2 (89.8 ± 4.6% versus 
91.4 ± 0.9%, respectively, p = 0.500).
Fat Biopsy Results
The body composition data of the OSA group, according to the 
impedance analysis, are as follows: body fat (BF) mass (BFM) 
40.6 ± 13.4 kg and BF 34.4 ± 6.9%, free fat mass (FFM) 74.7 ± 
8.0  kg, total body water 54.7 ± 5.9%, and basal metabolic rate 
2281 ± 302 kcal/day. Adipose tissue examination, as assessed on 
a scale from 0 to 6, revealed 3.8 ± 1.0 severity of fibrosis, 2.5 ± 1.4 
density of vascular structures, 1.4 ± 1.0 B and T lymphocytes, and 
3.2 ± 2.1 tissue macrophages. The data of each patient separately 
are presented in Table 3.
Waist circumference correlated positively with BFM (r = 0.971, 
p < 0.001) and BF (r = 0.852, p = 0.004). Also, neck circumference 
correlated with BFM (r = 0.880, p = 0.002) and BF (r = 0.732, 
p = 0.025). Hip circumference correlated with neither BFM (r = 
-0.181, p = 0.641) nor BF (r = -0.416, p = 0.265). Sleep efficiency 
(SE) correlated negatively with waist circumference (r = -0.791, 
p = 0.006), neck circumference (r = -0.790, p = 0.006), BFM (r = 
-0.787, p = 0.012), and BF (r = -0.767, p = 0.016).
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In the OSA group, macrophage accumulation in fat biopsy 
correlated positively with HADS-A score (r = 0.82, p = 0.047) 
but not with ESS, FSS, and HADS-D scores (Figure 2). Severity 
of fibrosis correlated largely with waist circumference (r = -0.56, 
p = 0.094), whereas density of vascular structures correlated 
positively with subjective duration of sleep (r = 0.68, p = 0.062) 
and negatively with respiratory events (r = -0.614, p = 0.05). The 
OSA group had lower B and T lymphocyte inflammation scores 
than the control group (p = 0.050, d = -1.09, large ES), whereas 
no difference was observed in severity of fibrosis (p  =  0.441, 
d = 0.43, small ES), density of vascular structure (p =  0.433, 
d = -0.43, small ES), and tissue macrophages (p = 0.967, d = 
-0.03, trivial ES; Figure 3). In the control group, severity of 
fibrosis correlated with HADS-D (r = -0.99, p = 0.011) and 
inflammation with FSS (r = -0.99, p = 0.010), whereas no other 
correlation was shown.
FIGURE 1 | Study protocol presenting the number of patients recruited, excluded, and included.
TABLE 1 | Baseline characteristics of the OSA patients and control group 
(mean ± SD).
Parameter OSA group Control group
Age (years) 47.4 ± 13.8 51.3 ± 11.3
BMI (kg/m2) 35.8 ± 4.8 34.2 ± 4.1
Neck circumference (cm) 44.3 ± 3.2 45.3 ± 2.3
Waist circumference (cm) 126.6 ± 16.5 133.8 ± 17.9
Hip circumference (cm) 109.8 ± 32.4 126.3 ± 2.1
Systolic arterial blood 
pressure (mmHg)
132.1 ± 8.1 133.8 ± 5.0
Diastolic arterial blood 
pressure (mmHg)
90.4 ± 6.2 90.0 ± 5.0
FVC (%) 92.0 ± 13.9 94.8 ± 6.7
FEV1 (%) 95.7 ± 13.9 90.1 ± 11.3
FEV1/FVC 84.6 ± 4.1 94.8 ± 5.4*
SaO2 96.4 ± 1.3 N/A
Glucose (mg/dl) 96.3 ± 8.6 103.5 ± 3.2
HbA1c 5.7 ± 0.5 N/A
Cholesterol 216.5 ± 42.8 206.8 ± 40.4
Triglycerides 166.0 ± 91.5 129.0 ± 21.2
HDL 36.5 ± 14.1 36.8 ± 7.0
LDL 145.6 ± 24.5 150.5 ± 39.7
AST 26.9 ± 9.1 28.3 ± 4.2
ALT 35.9 ± 24.3 41.8 ± 20.2
LDH 238.0 ± 47.2 207.5 ± 7.6
ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate 
dehydrogenase; LDL, low-density lipoprotein; HDL, high-density lipoprotein. *p = 0.001.
TABLE 2 | Sleep characteristics of the study population (mean ± SD).
Total recording time (min) 233.9 ± 116.0
TST (min) 204.4 ± 114.7
SE (%) 85.8 ± 13.4
Sleep onset (min) 12.4 ± 14.0
N1 (min) 35.8 ± 61.8
N2 (min) 108.5 ± 43.2
N3 (min) 49.5 ± 68.2
REM (min) 10.3 ± 16.0
Apneas+hypopneas (n) 234.4 ± 129.8
Obstructive apneas (n) 89.9 ± 66.4
Central apneas (n) 23.4 ± 28.5
Mixed apneas (n) 15.2 ± 32.4
Hypopneas (n) 95.2 ± 76.2
AHI 79.4 ± 46.1
Mean SaO2 (%) 90.0 ± 4.6
Min SaO2 (%) 78.7 ± 8.4
SaO2 < 90% (%) 10.3 ± 21.8
N1, stage 1; N2, stage 2; N3, stage 3–4; TST, total sleep time.
OSA, Psychological Symptoms, and Metabolic DiseaseTrakada et al.
5 July 2019 | Volume 10 | Article 527Frontiers in Psychiatry | www.frontiersin.org
DISCUSSION
To our knowledge, this is the first study to use fat biopsy to assess 
a complex interaction among OSA, psychological symptoms, and 
dysfunction of VAT. According to our findings, the dysregulation of 
the abdomen fat in OSA is triggered by different stimuli. Reduced 
SE is associated with increased waist circumference and fat mass, 
whereas anxiety symptoms promote macrophage accumulation, 
and repetitive respiratory events during sleep—apneas and 
hypopneas—reduce the extent of vascularization in abdomen fat.
In accordance to previous studies, the waist circumference 
of our population correlated with fat mass and BF (17). The 
measurement of abdominal obesity is known to be strongly 
associated with increased cardiometabolic risk, cardiovascular 
events, and mortality (17). Although waist circumference is a 
crude measurement, it correlates with obesity and visceral fat 
amount and is a surrogate marker for IR (17). Moreover, waist 
circumference predicts better OSA than neck or hip circumference 
(8). Visceral obesity is characterized by an overgrowth of adipose 
tissue that leads to the formation of hypoxic areas within this 
tissue due to mechanical reasons. Adipose tissue hypoxia is one 
of the earliest events in adipose tissue dysfunction that induces a 
local state of ﬁbrosis in the tissue (18).
The novel finding of our study was the relation between anxiety 
symptoms in OSA patients and the accumulation of macrophages 
in adipose tissue, which represents the key event in the induction 
of inflammation. Interestingly, depressive symptoms did not 
correlate with the accumulation of macrophages. According to 
current evidence, macrophages progressively infiltrate the adipose 
tissue during obesity, initiate the pro-inflammatory response by 
producing tumor necrosis factor-α (TNF-α) and interleukin (IL)-
6, and block adipocyte insulin action, a contributing factor in 
the development of IR and type 2 diabetes mellitus (19, 20). The 
overgrowth of adipose tissue leads to local tissue hypoxia, fibrosis, 
and finally adipocyte death by necrosis, which promotes the 
further recruitment of macrophages to scavenge the resulting cell 
debris (21). However, what exactly triggers the initial activation 
and infiltration of macrophages during obesity remains unclear. 
According to our data, symptoms of anxiety could be implicated 
in the accumulation of macrophages in abdomen fat.
The prevalence of anxiety in OSA ranges between 11% and 70% 
(22). According to a recent study, OSA patients have 3.68 times 
increased odds of anxiety and 2.88 times increased odds of severe 
psychological distress (23). Patients with OSA and anxiety differ 
in brain imaging of metabolic and structural disorders from those 
with OSA alone (24). Increased sympathetic activity associated 
with anxiety, brain alterations, and inflammatory mediators can 
contribute to the pathogenesis of OSA and vice versa (10).
We also confirmed a negative effect of the number of apneas and 
hypopneas during sleep on the extent of vascularization into visceral 
fat. Cumulative evidence points a causal relationship between OSA 
and cardiovascular and metabolic dysfunction independent of 
obesity (10). Several factors, such as oxidative stress, inflammation, 
and hypersecretion of adipocyte-derived hormones due to repetitive, 
short periods of asphyxia and hypoxemia and sleep deprivation 
may contribute to the complicated pathophysiologic cascade of 
events in OSA. Especially, this particular form of IH observed 
in OSA, with repetitive short cycles of desaturation followed by 
rapid reoxygenation, seems to dysregulate glucose metabolism 
through various mechanisms. We have shown previously that, 
TABLE 3 | Data of fat biopsy and body composition.
Patient (n) Severity of fibrosis 
(0–6)
Density of vascular 
structures (0–6)
B and T 
lymphocytes (0–6)
Tissue 
macrophages (0–6)
Fat mass (kg) FFM (kg)
1 5 1 1 2 26.1 65.9
2 2 4 1 6 61.2 70.2
3 3 4 2 6 43.9 79.1
4 4 1 1 3 43.2 90.6
5 4 1 1 5 29.2 69.3
6 3 2 1 1 77.9 93
7 3 4 1 2 50 70
8 4 4 1 1
9 5 2 4 5 24.4 63.3
FIGURE 2 | Relationship between macrophage accumulation in fat biopsy and HADS-A score (r = 0.82, p = 0.047; A), density of vascular structures and respiratory 
events (r = -0.614, p = 0.05; B), and SE and waist circumference (r = -0.791, p = 0.006; C) in the OSA group.
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in non-diabetic male OSA patients without comorbidities, the 
number of respiratory cessation events, the indices of hypoxemia 
during sleep, and the arousal index were associated with increased 
fasting glucose and HbA1c levels (25). Furthermore, a U-share 
relation was observed between fasting plasma glucose levels and 
OSA severity, regardless of obesity, as expressed by BMI (26). 
Moreover, the variability of glucose levels and arterial pressure was 
also associated with the number of apneas and hypopneas and the 
degree of oxygenation during sleep (27). Finally, male OSA patients 
with no prior history of cardiovascular disease had significantly 
higher C-reactive protein levels and lower flow-mediated dilation 
values compared to control subjects, indicating the possible 
presence of subclinical atherosclerosis and subsequent increased 
risk for developing cardiovascular disease (28). The impact of 
respiratory events on visceral fat may represent another possible 
underlying mechanism of the cardiometabolic risk in OSA patients.
Both the state of hyperarousal due to anxiety symptoms and 
the sleep fragmentation due to repetitive apneas and hypopneas 
reduce SE. According to our data, reduced SE further increases fat 
mass and waist circumference. All these complex pathophysiologic 
mechanisms could interact in a vicious cycle that further aggravates 
sleep apnea.
Another interesting finding of our study was the observed 
difference in adipose tissue composition between apneic, obese 
male and non-apneic, obese controls. It is well known that 
macrophages act either as pro-inflammatory (M1 phenotype) to 
stimulate inflammation or as “meta-inflammatory” (M2 phenotype) 
to reduce inflammation (29). M2 adipose tissue macrophages are 
mainly maintained by the action of lymphocytes. However, obesity 
suppresses the recruitment of these lymphocytes to abdominal fat 
and down-regulates tolerogenic CD4+ T-regulatory cells, which 
could also lead to meta-inflammation (30, 31). As our OSA 
patients had lower B and T lymphocyte inflammation scores than 
the control group, we could hypothesize that sleep apnea further 
suppresses the “meta-inflammatory” process and increases the 
cardiometabolic risk.
The main strength of our study is the novelty of our data. 
However, the study has several limitations. One is the relatively 
restricted number of patients and the lack of women in the 
sample; certainly, our findings have to be verified on a larger 
scale. Moreover, due to the small number of participants, we 
cannot distinguish different groups according to severity of OSA 
(mild, moderate, or severe) or according to different phenotypes 
(sleepy versus non-sleepy, fatigued versus non-fatigued, etc.). 
OSA is a heterogeneous disease characterized by different clinical 
outcomes and prognosis despite similar AHI. Finally, we did not 
measure markers of inflammation, such as TNF-α, or Il-6, or 
indices of IR in the blood.
FIGURE 3 | Severity of fibrosis and density of vascular structures, inflammatory cells, and tissue macrophages in OSA patients and controls. *P ≤ 0.05.
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According to our data, anxiety symptoms may promote 
macrophage accumulation, and an increased number of respiratory 
events can reduce the extent of vascularization in visceral fat, 
whereas reduced SE can worsen indices of obesity in severe OSA. 
These complex interactions should be evaluated in larger studies 
to clarify the mechanisms underlying inflammation in OSA and to 
identify potential targets for clinical intervention.
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